[go: up one dir, main page]

MX2010011055A - Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas. - Google Patents

Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.

Info

Publication number
MX2010011055A
MX2010011055A MX2010011055A MX2010011055A MX2010011055A MX 2010011055 A MX2010011055 A MX 2010011055A MX 2010011055 A MX2010011055 A MX 2010011055A MX 2010011055 A MX2010011055 A MX 2010011055A MX 2010011055 A MX2010011055 A MX 2010011055A
Authority
MX
Mexico
Prior art keywords
ectopetidases
enkephalin
degrading
peptide derivatives
potent inhibitors
Prior art date
Application number
MX2010011055A
Other languages
English (en)
Inventor
Catherine Rougeot
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2010011055A publication Critical patent/MX2010011055A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención de refiere a péptidos modificados de opiorfina como nuevos inhibidores de metalo-ectopeptidasas.
MX2010011055A 2008-04-07 2009-04-07 Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas. MX2010011055A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4292208P 2008-04-07 2008-04-07
PCT/EP2009/054171 WO2009124948A1 (en) 2008-04-07 2009-04-07 Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopetidases

Publications (1)

Publication Number Publication Date
MX2010011055A true MX2010011055A (es) 2011-02-21

Family

ID=40956908

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011055A MX2010011055A (es) 2008-04-07 2009-04-07 Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.

Country Status (21)

Country Link
US (3) US8889827B2 (es)
EP (1) EP2274321B1 (es)
JP (2) JP5788788B2 (es)
KR (1) KR20110028433A (es)
CN (1) CN102083851A (es)
AU (1) AU2009235484B2 (es)
BR (1) BRPI0906905B1 (es)
CA (1) CA2720778C (es)
CY (1) CY1121966T1 (es)
DK (1) DK2274321T3 (es)
ES (1) ES2714374T3 (es)
HR (1) HRP20190335T1 (es)
HU (1) HUE042998T2 (es)
IL (1) IL208543A (es)
LT (1) LT2274321T (es)
MX (1) MX2010011055A (es)
PL (1) PL2274321T3 (es)
PT (1) PT2274321T (es)
RU (2) RU2542365C2 (es)
SI (1) SI2274321T1 (es)
WO (1) WO2009124948A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1577320B1 (en) 2004-03-19 2012-07-18 Institut Pasteur Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides
MX2010011055A (es) * 2008-04-07 2011-02-21 Pasteur Institut Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.
FR2931362B1 (fr) * 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
ES2315753T3 (es) * 1999-06-23 2009-04-01 Institut Pasteur Composiciones para el tratamiento de problemas de relaciones interpersonales y trastornos del comportamiento.
ES2235806T3 (es) * 2000-12-22 2005-07-16 Institut Pasteur Procedimiento de seleccion de moleculas ligando que se unen especificamente al sitio de union nep para el prentapeptido qhnpr.
RU2223113C1 (ru) * 2002-05-29 2004-02-10 Золотарев Юрий Александрович Пептид, обладающий регулирующей биологической активностью на белковый синтез в гепатоцитах
EP1577320B1 (en) 2004-03-19 2012-07-18 Institut Pasteur Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides
WO2008009276A1 (de) * 2006-07-21 2008-01-24 Jenoptik Laser, Optik, Systeme Gmbh Lateral verstellbare fassung für optische elemente
EP2111410A2 (en) * 2007-02-02 2009-10-28 Greenpharma Peptide inhibitors of metallo- ectopeptidases, compositions comprising said compounds and their pharmaceutical and cosmetic uses
WO2009090265A1 (en) * 2008-01-18 2009-07-23 Institut Pasteur Method for identifying bplp and opiorphin agonists or antagonists
MX2010011055A (es) * 2008-04-07 2011-02-21 Pasteur Institut Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
CA2645452A1 (en) 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker

Also Published As

Publication number Publication date
JP2015110651A (ja) 2015-06-18
IL208543A0 (en) 2010-12-30
WO2009124948A1 (en) 2009-10-15
SI2274321T1 (sl) 2019-04-30
US8889827B2 (en) 2014-11-18
US8642729B2 (en) 2014-02-04
AU2009235484B2 (en) 2013-11-07
EP2274321B1 (en) 2018-12-05
BRPI0906905A2 (pt) 2021-06-29
RU2014153924A (ru) 2016-07-20
CA2720778C (en) 2017-10-17
BRPI0906905B1 (pt) 2022-09-13
US20110124571A1 (en) 2011-05-26
IL208543A (en) 2016-10-31
HRP20190335T1 (hr) 2019-05-03
US20150065683A1 (en) 2015-03-05
HUE042998T2 (hu) 2019-07-29
CA2720778A1 (en) 2009-10-15
RU2542365C2 (ru) 2015-02-20
JP5788788B2 (ja) 2015-10-07
CY1121966T1 (el) 2020-10-14
KR20110028433A (ko) 2011-03-18
JP2011517940A (ja) 2011-06-23
DK2274321T3 (en) 2019-03-18
AU2009235484A1 (en) 2009-10-15
PT2274321T (pt) 2019-03-21
US20090253639A1 (en) 2009-10-08
LT2274321T (lt) 2019-03-12
EP2274321A1 (en) 2011-01-19
RU2010145158A (ru) 2012-05-20
US9273094B2 (en) 2016-03-01
CN102083851A (zh) 2011-06-01
ES2714374T3 (es) 2019-05-28
PL2274321T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
SG10201407927UA (en) Imidazopyridine derivatives as jak inhibitors
MX2008011976A (es) Composiciones farmaceuticas.
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IL212786A0 (en) New 4 - amino - 4 - oxobutanoyl peptides as inhibitors of viral replication
PL2320927T3 (pl) Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
MX2011011272A (es) Procesos e intermediarios.
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
MX2011012623A (es) Construcciones de casb7439.
CY1121966T1 (el) Παραγωγα πεπτιδιου οπιορφινης ως ισχυροι αναστολεις εκτοπεπτιδασων αποδομησεως εγκεφαλινης
MX2010003056A (es) Polimorfos de valomaciclovir.
IT1397023B1 (it) Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
EA201071163A1 (ru) Применение дефенсинов против менингита
AU2010294240A8 (en) PLGF-1 in homodimeric form
UY34485A (es) Inhibidores de la péptido desformilasa
MX2009003196A (es) Proceso para la preparacion de y-butirolactonas.
UA90643C2 (en) Process for the preparation of 2-bromosulpholene-2
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5
IN2012DN02721A (es)
PH12012501972A1 (en) Crystalline peptide epoxyketone immunoproteasome inhibitor

Legal Events

Date Code Title Description
FG Grant or registration